Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464725 | 0.81 | HCAR2 (0.45) | TAAR1LMNAHCAR2ADRA2AADRA2B | |
| SCHEMBL27704702 | 0.81 | NPSR1 (0.39) | TAAR1LMNAHCAR2FFAR1AOC3 | |
| SCHEMBL7853355 | 0.79 | HCAR2 (0.41) | TAAR1LMNAHCAR2ADRA2AADRA2B | |
| SCHEMBL10601685 | 0.79 | TSHR (0.43) | TAAR1FFAR1 | |
| SCHEMBL27592145 | 0.79 | LTA4H (0.43) | LMNAHTR2A | |
| SCHEMBL1289371 | 0.78 | TAAR1 (0.41) | TAAR1LMNAHCAR2FFAR1AOC3 | |
| SCHEMBL27770216 | 0.78 | TSHR (0.41) | TAAR1LMNAFFAR1 | |
| SCHEMBL20012560 | 0.77 | L3MBTL1 (0.44) | TAAR1LMNAPOLBLTB4RLTB4R2 | |
| SCHEMBL11982736 | 0.77 | L3MBTL1 (0.44) | TAAR1LMNAPOLBLTB4RLTB4R2 | |
| Isopropylbenzene SCHEMBL1927763 | 0.77 | TAAR1 (0.43) | TAAR1LMNAPOLBAOC3TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013795-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3890778-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | Agensys, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021030240-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2020117373-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20170112129-A1 | NOVEL PYRAZOLYLTRIAZOLYLPYRIDINES AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2017-04-27 | — | — | US | disclosed |
| EP-2621526-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Agensys, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2533804-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | Agensys, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2490720-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012047724-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2011097627-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011050242-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2006010567-A1 | SUBSTITUTED PYRIDO[3', 2': 4, 5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3', 2': 4, 5]FURO[3, 2, D]PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF$G(A) | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112129-A1 | NOVEL PYRAZOLYLTRIAZOLYLPYRIDINES AS PESTICIDES | PRDX4, PRDX1, PRDX5 | TAAR1 515/4885LMNA 3379/4885POLB 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.